Investor Relations

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The Company’s lead product candidate, galinpepimut-S (GPS), is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a broad spectrum of hematologic cancers and solid tumor indications. SELLAS commenced a pivotal Phase 3 clinical trial of GPS in patients with AML in January 2020.

Latest News